Pardes Biosciences Shares Early Data From COVID-19 Study
Pardes Biosciences Inc's (NASDAQ: PRDS) has
Related Posts
Piper Sandler Maintains Neutral on Heska, Raises Price Target to $107
Piper Sandler maintains Heska (NASDAQ:HSKA) with a Neutral and raises the price target from $86 to $107.
SpartanNash Pharmacies Hosting COVID-19 Vaccine Booster Clinics In October
As part of its continued efforts to champion a People First culture and promote the wellbeing and safety of its family of Associates, customers and communities during the coronavirus pandemic, food solutions
Alibaba, JD Buck The Trend As Hang Seng Extends Losses On Tighter COVID-19 Rules
Shares of Alibaba Group Holding Limited (NYSE: BABA), Xpeng Inc. (NYSE: XPEV), Baidu Inc. (NASDAQ: BIDU) and